209 related articles for article (PubMed ID: 18829559)
41. Development of a preliminary physiologically based toxicokinetic (PBTK) model for 1,3-butadiene risk assessment.
Sweeney LM; Himmelstein MW; Gargas ML
Chem Biol Interact; 2001 Jun; 135-136():303-22. PubMed ID: 11397398
[TBL] [Abstract][Full Text] [Related]
42. A preliminary regional PBPK model of lung metabolism for improving species dependent descriptions of 1,3-butadiene and its metabolites.
Campbell J; Van Landingham C; Crowell S; Gentry R; Kaden D; Fiebelkorn S; Loccisano A; Clewell H
Chem Biol Interact; 2015 Aug; 238():102-10. PubMed ID: 26079054
[TBL] [Abstract][Full Text] [Related]
43. Urinary butadiene diepoxide: a potential biomarker of blood diepoxide.
Henderson RF; Bechtold WE; Thornton-Manning JR; Dahl AR
Toxicology; 2001 Mar; 160(1-3):81-6. PubMed ID: 11246127
[TBL] [Abstract][Full Text] [Related]
44. Evaluation of potential human carcinogenicity of the synthetic monomer ethyl acrylate.
Williams GM; Iatropoulos MJ
Regul Toxicol Pharmacol; 2009 Feb; 53(1):6-15. PubMed ID: 18930102
[TBL] [Abstract][Full Text] [Related]
45. Estimation of the cancer risk of genotoxic chemicals by the rad-equivalence approach.
Kolman A; Segerbäck D; Osterman-Golkar S
IARC Sci Publ; 1988; (89):258-64. PubMed ID: 3198207
[TBL] [Abstract][Full Text] [Related]
46. Assessment of the carcinogenic potential of mitemcinal (GM-611): increased incidence of malignant lymphoma in a rat carcinogenicity study.
Fujii E; Kimura K; Mizoguchi K; Kato A; Takanashi H; Itoh Z; Omura S; Suzuki M
Toxicol Appl Pharmacol; 2008 Apr; 228(1):1-7. PubMed ID: 18355581
[TBL] [Abstract][Full Text] [Related]
47. A physiological toxicokinetic model for 1,3-butadiene in rodents and man: blood concentrations of 1,3-butadiene, its metabolically formed epoxides, and of haemoglobin adducts--relevance of glutathione depletion.
Csanády GA; Kreuzer PE; Baur C; Filser JG
Toxicology; 1996 Oct; 113(1-3):300-5. PubMed ID: 8901913
[TBL] [Abstract][Full Text] [Related]
48. Literature review on the genotoxicity, reproductive toxicity, and carcinogenicity of ethyl methanesulfonate.
Gocke E; Bürgin H; Müller L; Pfister T
Toxicol Lett; 2009 Nov; 190(3):254-65. PubMed ID: 19857796
[TBL] [Abstract][Full Text] [Related]
49. A model of sensitivity: 1,3-butadiene increases mutant frequencies and genomic damage in mice lacking a functional microsomal epoxide hydrolase gene.
Wickliffe JK; Ammenheuser MM; Salazar JJ; Abdel-Rahman SZ; Hastings-Smith DA; Postlethwait EM; Lloyd RS; Ward JB
Environ Mol Mutagen; 2003; 42(2):106-10. PubMed ID: 12929123
[TBL] [Abstract][Full Text] [Related]
50. Comparison of genotoxic potency of styrene 7,8-oxide with gamma radiation and human cancer risk estimation of styrene using the rad-equivalence approach.
Godderis L; Aka P; Kirsch-Volders M; Veulemans H
Mutagenesis; 2007 May; 22(3):209-15. PubMed ID: 17311804
[TBL] [Abstract][Full Text] [Related]
51. The stability of historical control data for common neoplasms in laboratory rats and the implications for carcinogenic risk assessment.
Tennekes H; Kaufmann W; Dammann M; van Ravenzwaay B
Regul Toxicol Pharmacol; 2004 Dec; 40(3):293-304. PubMed ID: 15546683
[TBL] [Abstract][Full Text] [Related]
52. Toward a molecular equivalent dose: use of the medaka model in comparative risk assessment.
Hobbie KR; Deangelo AB; King LC; Winn RN; Law JM
Comp Biochem Physiol C Toxicol Pharmacol; 2009 Mar; 149(2):141-51. PubMed ID: 18722551
[TBL] [Abstract][Full Text] [Related]
53. 1,3-Butadiene: linking metabolism, dosimetry, and mutation induction.
Bond JA; Csanady GA; Gargas ML; Guengerich FP; Leavens T; Medinsky MA; Recio L
Environ Health Perspect; 1994 Nov; 102 Suppl 9(Suppl 9):87-94. PubMed ID: 7698092
[TBL] [Abstract][Full Text] [Related]
54. The Viracept (nelfinavir)--ethyl methanesulfonate case: a threshold risk assessment for human exposure to a genotoxic drug contamination?
Lutz WK
Toxicol Lett; 2009 Nov; 190(3):239-42. PubMed ID: 19695319
[TBL] [Abstract][Full Text] [Related]
55. Assessment of the potential risk to workers from exposure to 1,3-butadiene.
Turnbull D; Rodricks JV; Brett SM
Environ Health Perspect; 1990 Jun; 86():159-71. PubMed ID: 2205486
[TBL] [Abstract][Full Text] [Related]
56. Prospective detection and assessment of genotoxic hazards: a critical appreciation of the contribution of L. Ehrenberg.
Wright AS; Bradshaw TK; Watson WP
IARC Sci Publ; 1988; (89):237-48. PubMed ID: 3058596
[TBL] [Abstract][Full Text] [Related]
57. Effect of n-hexane on the disposition and toxicity of the 1,3-butadiene metabolite 3-butene-1,2-diol.
Iba MM; Bird MG
Chem Biol Interact; 2007 Mar; 166(1-3):232-8. PubMed ID: 16935275
[TBL] [Abstract][Full Text] [Related]
58. Quantitative assessment of cumulative carcinogenic risk for multiple genotoxic impurities in a new drug substance.
Bercu JP; Hoffman WP; Lee C; Ness DK
Regul Toxicol Pharmacol; 2008 Aug; 51(3):270-7. PubMed ID: 18550240
[TBL] [Abstract][Full Text] [Related]
59. Parallelogram based approach for in vivo dose estimation of genotoxic metabolites in humans with relevance to reduction of animal experiments.
Motwani HV; Frostne C; Törnqvist M
Sci Rep; 2017 Dec; 7(1):17560. PubMed ID: 29242644
[TBL] [Abstract][Full Text] [Related]
60. An evaluation of the mode of action framework for mutagenic carcinogens case study: Cyclophosphamide.
McCarroll N; Keshava N; Cimino M; Chu M; Dearfield K; Keshava C; Kligerman A; Owen R; Protzel A; Putzrath R; Schoeny R
Environ Mol Mutagen; 2008 Mar; 49(2):117-31. PubMed ID: 18240158
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
